Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women: a report from the Shanghai Breast Cancer Study
暂无分享,去创建一个
X. Shu | W. Zheng | Q. Cai | W. Wen | S. Deming | Z. Ren | Yu-Tang Gao | Yu-Tang Gao
[1] A. Neugut,et al. IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project. , 2006, Carcinogenesis.
[2] J. Chang-Claude,et al. Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study , 2006, British Journal of Cancer.
[3] D. Altshuler,et al. IGF-I Genetic Variation and Breast Cancer: the Multiethnic Cohort , 2006, Cancer Epidemiology Biomarkers & Prevention.
[4] J. Chang-Claude,et al. Genetic Variation in the Growth Hormone Synthesis Pathway in Relation to Circulating Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-3, and Breast Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition Study , 2005, Cancer Epidemiology Biomarkers & Prevention.
[5] I. Ellis,et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. , 2005, Endocrine-related cancer.
[6] K. Hemminki,et al. Polymorphisms in the IGF-1 and IGFBP3 promoter and the risk of breast cancer , 2005, Breast Cancer Research and Treatment.
[7] J. Ryś,et al. Lack of synergy between estrogen and progesterone on local IGF-I, IGFBP-3 and IGFBP-2 secretion by both hormone-dependent and hormone-independent breast cancer explants in vitro. Effect of tamoxifen and mifepristone (RU 486). , 2005, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.
[8] A. Roddam,et al. A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk , 2005, British Journal of Cancer.
[9] X. Shu,et al. Insulin‐like growth factor‐I gene polymorphism and breast cancer risk in Chinese women , 2005, International journal of cancer.
[10] A. Tjønneland,et al. Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[11] M. Bartucci,et al. Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer. , 2004, Journal of experimental & clinical cancer research : CR.
[12] X. Shu,et al. Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[13] Matthias Egger,et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.
[14] X. Shu,et al. Evaluation of the synergistic effect of insulin resistance and insulin‐like growth factors on the risk of breast carcinoma , 2004, Cancer.
[15] A. Schulz,et al. Insulin-like growth factor I (IGF-I) stimulates proliferation but also increases caspase-3 activity, Annexin-V binding, and DNA-fragmentation in human MG63 osteosarcoma cells: co-activation of pro- and anti-apoptotic pathways by IGF-I. , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[16] D. Hunter,et al. Polymorphic variation at the ‐202 locus in IGFBP3: Influence on serum levels of insulin‐like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk , 2003, International journal of cancer.
[17] T. Habuchi,et al. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. , 2003, Cancer research.
[18] F. Horn,et al. IGFs, basic FGF, and glucose modulate proliferation and apoptosis induced by IFNgamma but not by IL-1beta in rat INS-1E beta-cells. , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[19] R. Krajcik,et al. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[20] F. Berrino,et al. Fasting glucose is a risk factor for breast cancer: a prospective study. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[21] F. Speizer,et al. A sequence repeat in the insulin‐like growth factor‐1 gene and risk of breast cancer , 2002, International journal of cancer.
[22] Peter H. Westfall,et al. Testing Association of Statistically Inferred Haplotypes with Discrete and Continuous Traits in Samples of Unrelated Individuals , 2002, Human Heredity.
[23] M. Stampfer,et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. , 2001, The Journal of clinical endocrinology and metabolism.
[24] R. Shore,et al. Serum insulin‐like growth factor‐I and breast cancer , 2000, International journal of cancer.
[25] T. Sellers,et al. Association of menstrual and reproductive factors with breast cancer risk: Results from the Shanghai breast cancer study , 2000, International journal of cancer.
[26] T. Hansen,et al. Studies of the variability of the genes encoding the insulin-like growth factor I receptor and its ligand in relation to type 2 diabetes mellitus. , 2000, The Journal of clinical endocrinology and metabolism.
[27] Y. Wu,et al. Plasma Insulin-Like Growth Factor-I and Serum IGF-Binding Protein 3 Can Be Associated with the Progression of Breast Cancer, and Predict the Risk of Recurrence and the Probability of Survival in African-American and Hispanic Women , 1999, Oncology.
[28] C. Mantzoros,et al. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. , 1998, Epidemiology.
[29] David J Hunter,et al. Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.
[30] C T Roberts,et al. Molecular and cellular aspects of the insulin-like growth factor I receptor. , 1995, Endocrine reviews.
[31] V. Macaulay,et al. Insulin-like growth factors and cancer. , 1992, British Journal of Cancer.
[32] M. Johnson,et al. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. , 1990, The Journal of biological chemistry.
[33] R. Humbel,et al. Insulin-like growth factors I and II. , 1990, European journal of biochemistry.
[34] P. Rotwein,et al. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. , 1989, Endocrine reviews.
[35] Nicholas J Wareham,et al. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. , 2006, Human molecular genetics.
[36] H. Huynh,et al. Tamoxifen reduces serum insulin-like growth factor I (IGF-I) , 2005, Breast Cancer Research and Treatment.
[37] H. Werner,et al. Molecular and cellular aspects of insulin-like growth factor action. , 1994, Vitamins and hormones.
[38] J. Bonneterre,et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. , 1993, European journal of cancer.
[39] C. Hagen,et al. Insulinlike Growth Factor Binding Proteins , 1990 .